GlassScriptPhysician profile
Scott R Nelson
NPI 1760589279
$11,839.43
in general payments reported to CMS, 2019-2025
40 companies · $1,974 in 2025
The $1,974 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,851 · 2020: $852 · 2021: $1,220 · 2022: $1,971 · 2023: $2,211 · 2024: $1,760 · 2025: $1,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,755 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,754.86 |
| Education | $191.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,795.54 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $918.93 | 2019-2023 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $769.58 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $720.69 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Novartis Pharmaceuticals Corporation | $654.48 | 2019-2024 | |
| Axsome Therapeutics, INC. | $568.27 | 2022-2025 | Sunosi |
| Pulmonx Corporation | $521.52 | 2019-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Mylan Specialty L.P. | $406.98 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $384.51 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $333.31 | 2021-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $322.14 | 2019-2024 | |
| Genzyme Corporation | $308.58 | 2019-2025 | |
| Electromed, INC. | $276.22 | 2019-2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $230.38 | 2020-2023 | Aralast |
| Grifols USA, LLC | $216.38 | 2022-2025 | Prolastin-C Liquid, Xembify |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $192.75 | 2025 | |
| Janssen Pharmaceuticals, INC | $160.88 | 2020-2023 | Xarelto |
| Baxter Healthcare | $154.61 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Cardiac Ambulatory Monitor |
| United Therapeutics Corporation | $117.90 | 2021-2024 | Tyvaso |
| Amgen INC. | $96.53 | 2024-2025 | Tezspire, Tavneos |
| Verona Pharma, INC. | $91.31 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $53.07 | 2023 | Acthar |
| Teva Pharmaceuticals USA, INC. | $51.93 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $51.85 | 2024 | Lumryz |
| Inspire Medical Systems, INC. | $50.58 | 2023-2025 | Inspire |
| Paratek Pharmaceuticals, INC. | $42.26 | 2019-2023 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $41.69 | 2019 | |
| Circassia INC. | $39.02 | 2019 | |
| Philips North America LLC | $37.30 | 2025 | Vest Therapy Und |
| Medical Graphics Corporation | $34.38 | 2020 | |
| Viatris Specialty LLC | $31.75 | 2025 | Yupelri |
| Abbott Laboratories | $24.87 | 2022 | |
| Pfizer INC. | $20.03 | 2023 | |
| Abbvie INC. | $19.48 | 2025 | |
| Insmed, INC. | $18.45 | 2025 | Brinsupri, Arikayce |
| Amarin Pharma, INC. | $17.74 | 2021 | |
| Inogen, INC. | $16.61 | 2024 | |
| Apria Healthcare LLC | $16.39 | 2021 | |
| Shire North American Group INC | $15.75 | 2019 | |
| Gilead Sciences, INC. | $14.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.